nnvc

axelvento

dCellVax
Registrato
21/12/04
Messaggi
16.246
Punti reazioni
419

ciao bella gioia:D
è stato un grande
scrive:

Lui è il primo ad ammettere che si tratta di una strategia rischiosa. E non è per tutti.
"Ho iniziato con l'apertura di un conto con $ 500 per vedere cosa avrei potuto ritirare dal mio conto, ha detto Grittani. "Ma nel giro di poche settimane ho perso metà del mio conto e ho deciso che avevo bisogno di qualche aiuto esterno".


aggiungo:
pensare sempre a quello che si ha in mano....
tutto puo' succedere
non farsi mai prendere dalla paura
è quella che ti frega:yes:

quindi essere pazienti
arriva sempre il tuo giorno di festa:yes:
e arriva il giorno che devi smettere per sempre
e andare a vivere ai caraibi sole mare tranquillita'
 

LOROCIU65

""ONLY THE BRAVE""
Registrato
1/3/06
Messaggi
31.837
Punti reazioni
689
hanno molta carne al fuoco..come pipeline.

Hanno fatto adc questi gg 4.25$... Vediamo dove si puo tentare un ingressino-
se poi qualkuno vuole esprimersi..NON LA CONOSCO..
 

axelvento

dCellVax
Registrato
21/12/04
Messaggi
16.246
Punti reazioni
419
2016
winnnnnnnnnnnnnnnnnnne$$$$$$$$$$$$$$$$$$

$1.12:eek::eek::eek::eek:
The Company estimates that it had approximately $29.7 Million (M) of current assets plus restricted cash (cash, cash equivalents, collateral advance, prepaid expenses, and security deposits) as of September 30, 2015, the end of the reporting period. The net cash used in operating activities during this quarter was approximately $1.65M, with an additional approximately $0.33M towards purchase of property and equipment. The Company reported a net loss of $0.02 per share for the quarter. Shareholder equity stood at approximately $30.71M for the quarter. The Company does not anticipate any major capital expenditures in the near future.

The Company estimates that the cash in hand is sufficient to enable us to perform initial human clinical trials of at least one of our drug candidates, as well as to advance at least one more drug candidate drug candidate towards initial human clinical trials.

The Company reports that its HerpeCide(TM) program is advancing well. We anticipate developing topical drugs to control herpesvirus outbreaks for a number of indications under this program. These include oral lesions or "cold sores", usually caused by HSV-1, genital lesions, usually caused by HSV-2, and shingles outbreaks in adults, caused by reactivation of the chickenpox virus (varicella Zoster virus, or HHV-3). In addition, the Company is also developing eye drops for the treatment of herpes keratitis (HK) of the eye, and for epidemic adenoviral conjunctivitis (EKC). The Company believes, assuming the results from our animal studies are indicative of future human clinical success, that these various drug candidates under the HerpeCide program should result in extremely effective drugs.

The Company believes, based on various professional inputs it has obtained, that the different topical herpesvirus treatments would move towards the clinical stage faster than our Injectable FluCide(TM) for hospitalized patients. This is based on the limited studies needed for safety/toxicology, as well as for efficacy, for a topical drug against herpesviruses, as opposed to an injectable drug against the highly variable influenza viruses.

We continue to work on Injectable FluCide in parallel with the HerpeCide program drug candidates.

The Company has completed its transition to its new facilities at 1 Controls Drive, Shelton, CT. With this state of the art facility, NanoViricides, Inc. is now one of the very few small pharma drug developers that possess their own clinical quality drug manufacturing operations. NanoViricides now has the facilities to design, synthesize, scale-up, and manufacture any of our drug substances for IND submissions and for human clinical trials, and also has the capability to manufacture sufficient drug substance for initial market entry when the drug is licensed. The new facilities include a state of the art, highly customizable, c-GMP-capable drug production suite with clean rooms for the production of injectable drugs in multi-kilogram batches. (IND = "investigational New Drug", c-GMP = "current Good Manufacturing Practice"). All of the biological testing of our drug candidates continues to be performed by external collaborators.

The Company believes that the drug substance requirement for any of the topical herpecide drug candidates would be in the range of a few hundred grams. The Company has already scaled up certain production steps to 200g scale or better, and the remaining steps are being scaled up, while developing appropriate process controls and characterization methods alongside. Thus the Company believes it will soon have the ability to produce the HerpeCide drug candidates in quantities sufficient for the safety/toxicology studies, and will be able to make similar quantities of c-GMP-quality material later for human clinical trials when needed.

The Company continues further work to scale up the production to 500g, 1kg and larger batch quantities as feasible in the new facility. Injectable FluCide safety/toxicology studies have been estimated to require more than 2kg of material.

The nanoviricides(R) mechanism of action is believed to mimic a natural host cell receptor using which the virus binds and infects cells; binding of a nanoviricide nanomicelle to the virus is expected to render it non-infectious. A nanoviricide would thus stop the spread of the viral infection to new uninfected cells. This mechanism is different from that of currently available anti-Herpes drugs. The Company therefore believes that it is able to develop broad-spectrum anti-herpes nanoviricide drugs.

The Company reports that all of its drug development programs are progressing satisfactorily and that it will continue to provide updates as
 

axelvento

dCellVax
Registrato
21/12/04
Messaggi
16.246
Punti reazioni
419
NanoViricides, Inc. (NYSE MKT: NNVC (the "Company") announced today that it has entered into an agreement with Baylor College of Medicine (Baylor) for the testing of its nanoviricides(R) drug candidates in a small animal model of ocular virus infections.

https://photos.prnewswire.com/prnvar/20150107/167444LOGO

The research will be supervised by Dr. Stephen Pflugfelder, Professor of Ophthalmology and the James and Margaret Elkins Chair in Ophthalmology at Baylor. Dr. Pflugfelder has extensive experience in ophthalmological research as well as in ocular drug development, including conducting clinical trials. The research will be performed in the laboratories of the Department of Ophthalmology.

These animal studies will evaluate the efficacy and potency of the Company's nanoviricides anti-viral agents in certain ocular viral infections. The goal of these studies is to help select clinical drug development candidates for treatment of certain ocular viral diseases including herpes keratitis in humans.

"We are very pleased to have the Baylor College of Medicine Department of Ophthalmology join our efforts in developing a drug against ocular viral infections including Herpes Keratitis," said Eugene Seymour, MD, MPH, CEO of the Company, adding, "We believe Dr. Pflugfelder and his lab will be able to guide us in the IND-enabling development of our drug candidates."

About NanoViricides: NanoViricides, Inc. (NanoViricides Inc: A New Era in Targeted Anti-Viral Therapeutics) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

Logo - Login

To view the original version on PR Newswire, visit:NanoViricides Signs Agreement for Ocular Testing of Its Drug Candidates for the... -- SHELTON, Conn., Feb. 16, 2016 /PRNewswire/ --

SOURCE NanoViricides, Inc.
 

axelvento

dCellVax
Registrato
21/12/04
Messaggi
16.246
Punti reazioni
419
xxxxxxxxxxxxxxxxx
 

Allegati

  • nnvc.png
    nnvc.png
    19,1 KB · Visite: 70